17ß-estradiol (1 mg) i drospirenon (2 mg) w terapii hormonalnej okresu pomenopauzalnego

Abstract

Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviatingclimacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, andhas a positive influence on lipid profile, carbohydrate metabolism, arterial pressure and female quality of life.This safe type of MHT can be a drug of first choice for the big group of women after menopause.

Keywords

• menopause
• drospirenone
• oestradiol
• oral hormonal therapy
• progestogens